vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Zscaler, Inc. (ZS). Click either name above to swap in a different company.
Zscaler, Inc. is the larger business by last-quarter revenue ($788.1M vs $761.7M, roughly 1.0× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs -1.5%, a 13.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 25.5%). Zscaler, Inc. produced more free cash flow last quarter ($431.0M vs $89.5M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 22.5%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Zscaler, Inc. is an American cloud security company based in San Jose, California. The company offers cloud-based services to protect enterprise networks and data.
PODD vs ZS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $761.7M | $788.1M |
| Net Profit | $91.1M | $-11.6M |
| Gross Margin | 69.5% | 76.6% |
| Operating Margin | 16.0% | -4.6% |
| Net Margin | 12.0% | -1.5% |
| Revenue YoY | 33.9% | 25.5% |
| Net Profit YoY | 157.3% | 3.6% |
| EPS (diluted) | $1.30 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $761.7M | — | ||
| Q4 25 | $783.7M | $788.1M | ||
| Q3 25 | $706.3M | $719.2M | ||
| Q2 25 | $649.1M | $678.0M | ||
| Q1 25 | $569.0M | $647.9M | ||
| Q4 24 | $597.5M | $628.0M | ||
| Q3 24 | $543.9M | $592.9M | ||
| Q2 24 | $488.5M | $553.2M |
| Q1 26 | $91.1M | — | ||
| Q4 25 | $101.6M | $-11.6M | ||
| Q3 25 | $87.6M | $-17.6M | ||
| Q2 25 | $22.5M | $-4.1M | ||
| Q1 25 | $35.4M | $-7.7M | ||
| Q4 24 | $100.7M | $-12.1M | ||
| Q3 24 | $77.5M | $-14.9M | ||
| Q2 24 | $188.6M | $19.1M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 72.6% | 76.6% | ||
| Q3 25 | 72.2% | 76.1% | ||
| Q2 25 | 69.7% | 77.0% | ||
| Q1 25 | 71.9% | 77.1% | ||
| Q4 24 | 72.1% | 77.5% | ||
| Q3 24 | 69.3% | 78.0% | ||
| Q2 24 | 67.7% | 78.6% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 18.7% | -4.6% | ||
| Q3 25 | 16.7% | -4.5% | ||
| Q2 25 | 18.7% | -3.7% | ||
| Q1 25 | 15.6% | -6.2% | ||
| Q4 24 | 18.3% | -4.9% | ||
| Q3 24 | 16.2% | -4.5% | ||
| Q2 24 | 11.2% | -0.5% |
| Q1 26 | 12.0% | — | ||
| Q4 25 | 13.0% | -1.5% | ||
| Q3 25 | 12.4% | -2.4% | ||
| Q2 25 | 3.5% | -0.6% | ||
| Q1 25 | 6.2% | -1.2% | ||
| Q4 24 | 16.9% | -1.9% | ||
| Q3 24 | 14.2% | -2.5% | ||
| Q2 24 | 38.6% | 3.5% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.42 | $-0.07 | ||
| Q3 25 | $1.24 | $-0.11 | ||
| Q2 25 | $0.32 | $-0.03 | ||
| Q1 25 | $0.50 | $-0.05 | ||
| Q4 24 | $1.38 | $-0.08 | ||
| Q3 24 | $1.08 | $-0.09 | ||
| Q2 24 | $2.59 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $480.4M | $1.3B |
| Total DebtLower is stronger | $18.6M | — |
| Stockholders' EquityBook value | $1.3B | $2.0B |
| Total Assets | $3.0B | $6.5B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $480.4M | — | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | $18.6M | — | ||
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.5B | $2.0B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.5B | $1.8B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.1B | $1.3B | ||
| Q2 24 | $998.4M | $1.1B |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.2B | $6.5B | ||
| Q3 25 | $3.0B | $6.4B | ||
| Q2 25 | $3.5B | $5.3B | ||
| Q1 25 | $3.5B | $5.0B | ||
| Q4 24 | $3.1B | $4.7B | ||
| Q3 24 | $3.0B | $4.7B | ||
| Q2 24 | $2.9B | $4.2B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | 0.64× | ||
| Q1 25 | 1.21× | 0.71× | ||
| Q4 24 | 1.07× | 0.80× | ||
| Q3 24 | 1.21× | 0.90× | ||
| Q2 24 | 1.36× | 1.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $113.8M | $448.3M |
| Free Cash FlowOCF − Capex | $89.5M | $431.0M |
| FCF MarginFCF / Revenue | 11.8% | 54.7% |
| Capex IntensityCapex / Revenue | 3.2% | 2.2% |
| Cash ConversionOCF / Net Profit | 1.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $415.7M | $924.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $113.8M | — | ||
| Q4 25 | $183.3M | $448.3M | ||
| Q3 25 | $125.7M | $250.6M | ||
| Q2 25 | $196.5M | $211.1M | ||
| Q1 25 | $63.8M | $179.4M | ||
| Q4 24 | $147.7M | $331.3M | ||
| Q3 24 | $98.5M | $203.6M | ||
| Q2 24 | $96.5M | $173.4M |
| Q1 26 | $89.5M | — | ||
| Q4 25 | $48.2M | $431.0M | ||
| Q3 25 | $100.1M | $190.6M | ||
| Q2 25 | $177.9M | $138.9M | ||
| Q1 25 | $51.5M | $164.4M | ||
| Q4 24 | $94.1M | $314.3M | ||
| Q3 24 | $71.8M | $154.2M | ||
| Q2 24 | $74.0M | $137.8M |
| Q1 26 | 11.8% | — | ||
| Q4 25 | 6.2% | 54.7% | ||
| Q3 25 | 14.2% | 26.5% | ||
| Q2 25 | 27.4% | 20.5% | ||
| Q1 25 | 9.1% | 25.4% | ||
| Q4 24 | 15.7% | 50.1% | ||
| Q3 24 | 13.2% | 26.0% | ||
| Q2 24 | 15.1% | 24.9% |
| Q1 26 | 3.2% | — | ||
| Q4 25 | 17.2% | 2.2% | ||
| Q3 25 | 3.6% | 8.3% | ||
| Q2 25 | 2.9% | 10.6% | ||
| Q1 25 | 2.2% | 2.3% | ||
| Q4 24 | 9.0% | 2.7% | ||
| Q3 24 | 4.9% | 8.3% | ||
| Q2 24 | 4.6% | 6.4% |
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 8.73× | — | ||
| Q1 25 | 1.80× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 0.51× | 9.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
ZS
Segment breakdown not available.
